| Efficacy and safety of de-escalation of antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of randomized clinical trials. | 2022 | Journal of Cardiovascular Pharmacology |
| Efficacy and safety of clopidogrel versus ticagrelor as part of dual antiplatelet therapy in acute coronary syndrome - a systematic review and meta-analysis. | 2022 | Journal of Cardiovascular Pharmacology |
| Comparison of clinical outcomes between ticagrelor and clopidogrel in acute coronary syndrome: a comprehensive meta-analysis. | 2022 | Frontiers in Cardiovascular Medicine |
| Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management. | 2022 | Pharmacotherapy |
| Comparison of prasugrel and ticagrelor for patients with acute coronary syndrome: a systematic review and meta-analysis. | 2022 | Cardiology |
| Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis. | 2022 | BMC Cardiovascular disorders |
| Comparison of ticagrelor with clopidogrel in East Asian patients with acute coronary syndrome: a systematic review and meta-analysis of randomized clinical trials. | 2022 | Journal of Cardiovascular Pharmacology |
| P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: a systematic review and meta-analysis. | 2022 | European Journal of Internal Medicine |
| Comparison of ticagrelor vs clopidogrel in addition to aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis. | 2022 | JAMA Neurology |
| Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: a meta-analysis. | 2022 | Frigid Zone Medicine |
| Acute coronary syndrome and renal impairment: a systematic review. | 2022 | Reviews in Cardiovascular Medicine |
| Impact of prasugrel and ticagrelor on platelet reactivity in patients with acute coronary syndrome: a meta-analysis. | 2022 | Frontiers in Cardiovascular Medicine |
| P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: meta-analysis. | 2022 | Journal of the Formosan Medical Association |
| Early vs. delayed initiation of treatment with P2Y12 inhibitors in patients with non-ST-segment elevation acute coronary syndrome: a systematic review and network meta-analysis of randomized controlled trials. | 2022 | Frontiers in Cardiovascular Medicine |
| Comparison of prasugrel and ticagrelor for patients with acute coronary syndrome: a systematic review and meta-analysis. | 2022 | Cardiology |
| Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. | 2022 | Frontiers in Pharmacology |
| Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis. | 2021 | Vascular Pharmacology |
| Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. | 2021 | European Heart Journal |
| Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis. | 2021 | JACC: Cardiovascular Interventions |
| De-escalation from prasugrel or ticagrelor to clopidogrel in patients with acute coronary syndrome managed with percutaneous coronary intervention: an updated meta-analysis of randomized clinical trials. | 2021 | American Journal of Cardiovascular Drugs |
| De-escalation of dual antiplatelet therapy in patients with acute coronary syndromes. | 2021 | Journal of the American College of Cardiology |
| Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. | 2021 | The Lancet |
| Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. | 2021 | BMC Neurology |
| Efficacy and safety of using dual versus monotherapy antiplatelet agents in secondary stroke prevention: systematic review and meta-analysis of randomized controlled clinical trials. | 2021 | Circulation |
| Antiplatelet regimens for Asian patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. | 2021 | Annals of Translational Medicine |
| Comparison of major bleeding in patients with acute coronary syndrome that underwent coronary artery bypass grafting treated with clopidogrel or ticagrelor: a systematic review and meta-analysis. | 2021 | F1000Research |
| Efficacy and safety of ticagrelor monotherapy in patients following percutaneous coronary intervention. | 2021 | Medicine |
| Efficacy and safety of low dose ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis. | 2020 | Postgraduate Medical Journal |
| Prasugrel vs ticagrelor for DAPT therapy in patients with ACS undergoing PCI: a systematic review and meta-analysis of randomized controlled trials. | 2020 | Cardiovascular Revascularization Medicine |
| Ticagrelor for the primary prevention of stroke in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. | 2020 | Journal of Thrombosis and Thrombolysis |
| Risk of bradyarrhythmia related to ticagrelor: a systematic review and meta-analysis. | 2020 | Pharmacological Research |
| Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis. | 2020 | BMC Cardiovascular Disorders |
| Prasugrel versus ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials. | 2020 | Cardiovascular Drugs and Therapy |
| The risk of dyspnea in patients treated with third-generation P2Y12 inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials. | 2020 | BMC Cardiovascular Disorders |
| P2Y 12 inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis. | 2020 | Heart |
| Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta‑analysis. | 2020 | Scientific Reports |
| Efficacy and safety of ticagrelor compared to clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis. | 2019 | Current Pharmaceutical Design |
| Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis. | 2019 | Drug Design, Development and Therapy |
| Prasugrel vs. ticagrelor for acute coronary syndrome patients undergoing percutaneous coronary intervention: a systematic review and meta‑analysis. | 2019 | American Journal of Cardiovascular Drugs |
| Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention. | 2018 | Medicine |
| Ticagrelor for stroke prevention in patients with vascular risk factors: a systematic review and meta-analysis. | 2018 | Journal of the Neurological Sciences |
| Effect of preoperative loading dose ticagrelor and clopidogrel on no-reflow phenomenon during intervention in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. | 2018 | Drug Design, Development and Therapy |
